Hyperliquid, a derivatives-focused Layer-1 blockchain, now holds $6.73 billion in circulating USDC, narrowly surpassing Solana's $6.72 billion. This shift marks Hyperliquid as the second-largest chain by USDC supply after Ethereum. Most of Hyperliquid's USDC comes from native issuance on its Ethereum-compatible layer, supported by partnerships with Circle and Coinbase. The platform uses USDC as collateral for its perpetual futures markets, creating a feedback loop that boosts its native HYPE token. This development diversifies stablecoin distribution across chains, reducing concentration risk for USDC.
Hyperliquid's circulating USDC has reached $6.73 billion, surpassing Solana's $6.72 billion. For readers following Hyperliquid's market context, here is Pluang's snapshot as of Sep 17, 2026 20:23 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable movers include Polkadot (DOT) at Rp18.374 with a 5.63% increase and a Pluang order activity of 38% Sell / 62% Buy, Avalanche (AVAX) at Rp134.956 up 5.39% with 44% Sell / 56% Buy, and Chainlink (LINK) at Rp200.037 rising 5.36% with 53% Sell / 47% Buy. Typical hold times on Pluang range from 63 to 120 days among these assets.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
